case_images: PMC5599881_01
case_images: Early (EPR, top panel) and late (LPR, bottom panel) phase reaction respectively 0, 5 and 6 h after injection of IgE-contained ScIg
case_images: 13223_2017_213_Fig1_HTML.jpg
case_images: PMC5599881_01_13223_2017_213_Fig1_HTML.jpg
case_images: Fig1
case_images: Twelve minutes after the first ScIg injection (different batch of the product for each patient) edema, confluent wheal and erythema occurred (Fig. 1, top panel). A typical late phase reaction occurred 4-6 h later (Fig. 1, bottom panel, different batch of the product for each patient).
case_images: Passive type I (anaphylactic) reaction after ongoing sensitization during initial subcutaneous immunoglobulins repacement therapy. Timeline of two CVID patients receiving initial ScIg therapy. Negative skin test before, but positive after replacement therapy with Subcuvia  was presented. a Patient with rhinoconjunctivitis and laryngeal edema occurring after exposure to grass pollens. Serum IgE level fluctuation was presented. It was tested retrospectively every 2 days when ScIg loading dose was given over the course of 2 weeks. Serum IgE level and short serum half-life do not reflect IgE elimination, but FcER expression and opsonization of immune cells that are source positive skin tests. b Patient with anaphylaxis after peanut exposition during home-based self-administration of ScIg. ScIg home administration, and "take peanut home" messages of guidelines may be the cause of anaphylactic complication. Noteworthy, still positive test with the gradual decrease of wheal was observed after switching ScIg product (Subcuvia  withdrawal) to another one (Hizentra ). The first product contains IgE, the other:does not
case_images: 13223_2017_213_Fig2_HTML.jpg
case_images: PMC5599881_03_13223_2017_213_Fig2_HTML.jpg
case_images: Fig2
case_images: IgE, rheumatoid factor:RF, anti-Rh, anti-A, anti-B blood group isohemagglutinins (Table 1; Fig. 2a). ScIg infusions (Table 1; Fig. 2a). Serum of first representative patient was collected during hospital-based initial replacement therapy and tested retrospectively. IgE serum level during cumulative ScIg substitution are presented in Fig. 2a. Interestingly, fast decrease of serum IgE to below borderline level (i.e. <0.35 kU/l by the immunocap system) was observed at +4 days after each transfusion of Subcuvia .   
case_images: PMC5599881_02
case_images: Passive type I (anaphylactic) reaction after ongoing sensitization during initial subcutaneous immunoglobulins repacement therapy. Timeline of two CVID patients receiving initial ScIg therapy. Negative skin test before, but positive after replacement therapy with Subcuvia  was presented. a Patient with rhinoconjunctivitis and laryngeal edema occurring after exposure to grass pollens. Serum IgE level fluctuation was presented. It was tested retrospectively every 2 days when ScIg loading dose was given over the course of 2 weeks. Serum IgE level and short serum half-life do not reflect IgE elimination, but FcER expression and opsonization of immune cells that are source positive skin tests. b Patient with anaphylaxis after peanut exposition during home-based self-administration of ScIg. ScIg home administration, and "take peanut home" messages of guidelines may be the cause of anaphylactic complication. Noteworthy, still positive test with the gradual decrease of wheal was observed after switching ScIg product (Subcuvia  withdrawal) to another one (Hizentra ). The first product contains IgE, the other:does not
case_images: 13223_2017_213_Fig2_HTML.jpg
case_images: PMC5599881_03_13223_2017_213_Fig2_HTML.jpg
case_images: Fig2
case_images: IgE, rheumatoid factor:RF, anti-Rh, anti-A, anti-B blood group isohemagglutinins (Table 1; Fig. 2a). ScIg infusions (Table 1; Fig. 2a). Serum of first representative patient was collected during hospital-based initial replacement therapy and tested retrospectively. IgE serum level during cumulative ScIg substitution are presented in Fig. 2a. Interestingly, fast decrease of serum IgE to below borderline level (i.e. <0.35 kU/l by the immunocap system) was observed at +4 days after each transfusion of Subcuvia .   
case_images: PMC5599881_03
case_images: Passive type I (anaphylactic) reaction after ongoing sensitization during initial subcutaneous immunoglobulins repacement therapy. Timeline of two CVID patients receiving initial ScIg therapy. Negative skin test before, but positive after replacement therapy with Subcuvia  was presented. a Patient with rhinoconjunctivitis and laryngeal edema occurring after exposure to grass pollens. Serum IgE level fluctuation was presented. It was tested retrospectively every 2 days when ScIg loading dose was given over the course of 2 weeks. Serum IgE level and short serum half-life do not reflect IgE elimination, but FcER expression and opsonization of immune cells that are source positive skin tests. b Patient with anaphylaxis after peanut exposition during home-based self-administration of ScIg. ScIg home administration, and "take peanut home" messages of guidelines may be the cause of anaphylactic complication. Noteworthy, still positive test with the gradual decrease of wheal was observed after switching ScIg product (Subcuvia  withdrawal) to another one (Hizentra ). The first product contains IgE, the other:does not
case_images: 13223_2017_213_Fig2_HTML.jpg
case_images: PMC5599881_03_13223_2017_213_Fig2_HTML.jpg
case_images: Fig2
case_images: IgE, rheumatoid factor:RF, anti-Rh, anti-A, anti-B blood group isohemagglutinins (Table 1; Fig. 2a). ScIg infusions (Table 1; Fig. 2a). Serum of first representative patient was collected during hospital-based initial replacement therapy and tested retrospectively. IgE serum level during cumulative ScIg substitution are presented in Fig. 2a. Interestingly, fast decrease of serum IgE to below borderline level (i.e. <0.35 kU/l by the immunocap system) was observed at +4 days after each transfusion of Subcuvia .   